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Abstract
Background: HAX-1 has been described as a protein potentially involved in carcinogenesis and especially
metastasis. Its involvement in regulation of apoptosis and cell migration along with some data indicating its
overexpression in cancer cell lines and tumors suggests that HAX-1 may play a role in neoplastic transformation.
Here we present the first systematic analysis of HAX-1 expression in several solid tumors.
Methods: Using quantitative RT-PCR, we have determined the mRNA levels of HAX1 splice variant I in several solid
tumors. We have also analyzed by semiquantitative and quantitative RT-PCR the expression of five HAX-1 splice
variants in breast cancer samples and in normal tissue from the same individuals. Quantitative PCR was also
employed to analyze the effect of estrogen on HAX1 expression in breast cancer cell line. Immunohistochemical
analysis of HAX-1 was performed on normal and breast cancer samples.
Results: The results reveal statistically important HAX1 up-regulation in breast cancer, lung cancer and melanoma,
along with some minor variations in the splicing pattern. HAX-1 up-regulation in breast cancer samples was
confirmed by immunohistochemical analysis, which also revealed an intriguing HAX-1 localization in the nuclei of
the tumor cells, associated with strong ER status.
Conclusion: HAX-1 elevated levels in cancer tissues point to its involvement in neoplastic transformation,
especially in breast cancer. The connection between HAX-1 nuclear location and ER status in breast cancer samples
remains to be clarified.
Background
HAX-1 (HS1 associated protein X-1, encoded by the
HAX1 gene) is an important target of study in the field
of cancer research on account of its involvement in reg-
ulation of apoptosis and cell migration, key processes in
carcinogenesis and metastasis.
The anti-apoptotic, cell-protecting properties of HAX-
1 as well as its interactions with apoptosis-related pro-
teins have been widely reported [1-3]. HAX-1 was
demonstrated to interact with proteins involved in mito-
chondrial membrane permeabilization and elements of
the mitochondrial mega-channel [4,5] as well as with
proteins directly involved in initiation and execution of
apoptosis [2,6,7] and with several viral proteins impor-
tant for cell survival [1,8,9]. Recently, it was observed
that HAX-1 is required for suppression of apoptosis in
lymphocytes and neurons, by presenting Omi/HtrA2 to
Parl processing [3]. Nevertheless, in spite of the large
body of data indicating its role in apoptosis, molecular
mechanisms of HAX-1-mediated cell protection still
remain to be clarified.
The most explicit role of HAX-1 has been suggested
by the studies on the pathogenesis of severe congenital
neutropenia (Kostmann disease). This immuno-defi-
ciency syndrome is characterized by the paucity of neu-
trophils in peripheral blood caused by a block in
promyelocyte/myelocyte maturation, associated with
their apoptosis. HAX1 mutations, leading to the inacti-
vation of the protein, were found in Kostmann patients,
indicating the involvement of HAX-1 in the functioning
of the immunological system as well as in apoptosis
[10].
HAX-1 multifunctionality manifests itself in a number
of reported interactions with other proteins. One of
these proteins is prohibitin. Prohibitin was initially
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scriptional activity, but was subsequently shown to loca-
lize in the mitochondrial inner membrane and form a
complex with VDAC, ANT2 and HAX-1, implying its
role in apoptosis [5]. It has been reported that in the
presence of ERa and estradiol, prohibitin translocates to
t h en u c l e u s ,p r o v i d i n gap o s s i b l el i n kb e t w e e nH A X - 1
and estrogen-receptor signaling. Another possible con-
nection to estrogen signaling is suggested by data from
microarray analysis, which has classified HAX1 (as one
of 172 out of 20,000 human genes) as estrogen-respon-
sive [11,12]. Thus, further analysis of HAX1 responsive-
ness to estrogen seems to be worthwhile.
Besides its involvement in apoptosis, HAX-1 has been
also implicated to function in regulation of cell migra-
tion [13,14]. The HAX-1 protein partner, HS1 [15], is
highly homologous to cortactin, a cytoskeletal protein
frequently overexpressed in cancer. Considering the
similarity between HS1 and cortactin [16], it is not sur-
prising that HAX-1 also binds the latter [13]. It has
been suggested in several reports [17,18] that cortactin
promotes tumor invasiveness and metastasis. While HS1
is expressed mostly in hematopoietic cells, cortactin is
present in all other tissues [19,20]. It interacts with the
Arp2/3 complex, promoting actin polymerization during
actin network reconstruction in motile cells. HAX-1 was
shown to form a complex with cortactin, the small
GTP-ase Rac and regulatory protein Ga13. Accordingly,
a model was proposed, in which Ga13, when bound to
HAX-1, stimulates migration, while in the absence of
HAX-1 it activates cell adhesion [13]. A more recent
report [14] demonstrates the role of HAX-1 in regula-
tion of carcinoma cell migration and invasion via cla-
thrin-mediated endocytosis of intergin avb6.T h e
interaction of HAX-1 with the IL-1a precursor which
has been shown to regulate human endothelial cell
migration in vitro [21] provides additional support for a
role in regulation of cell migration.
Since the inhibition of apoptosis and the induction of
cell invasiveness are crucial for carcinogenesis, it is logi-
cal to expect that HAX-1 overexpression in neoplastic
cells should contribute to tumor resistance to apoptosis
as well as to the enhancement of metastatic potential.
HAX-1 overexpression has been observed in lesional
psoriasis, a chronic inflammatory disease in which dif-
ferentiation of keratinocytes is disturbed due to abnor-
mal resistance to apoptosis [22]. In the same report,
HAX-1 was shown to be overexpressed in melanoma
cell lines. HAX-1 overexpression was also observed in
oral squamous cell carcinoma (SCC) samples [14].
HAX-1 up-regulation in skin cancer samples and cell
lines, its involvement in pathology of skin disease and
the chromosomal location of the HAX1 gene within the
epidermal differentiation complex (chromosome 1q21)
suggests its role in maturation of the human epidermis.
This conclusion points to its possible involvement in
development of melanoma.
Except for the reports demonstrating HAX-1 over-
expression in SSC samples and a few cancer cell lines,
to date, the only available results concerning its expres-
sion in cancer consist of data from microarray and
SAGE analyses. According to Oncomine, [23], a cancer
microarray database, HAX1 is overexpressed in hepa-
toma, lung cancer, lymphoma, melanoma, leukemia and
myeloma - in order of decreasing statistical significance.
Downregulation of expression was observed for brain
cancer, ovarian cancer and seminoma. In breast cancer,
statistically significant overexpression correlated with
carcinoma grade. In a gene expression profiling study
utilizing SAGE, HAX1 overexpression was demonstrated
to be specifically induced by hypoxia in renal cell carci-
noma (RCC) cells [24]. Althought h e s er e p o r t si n d i c a t e
HAX1 overexpression in cancer, their reliability is not as
high as in the focused study, so they still need to be ver-
ified by more systematic analysis.
HAX1 was shown to be expressed quite ubiquitously
in human tissues, with relatively higher expression in
testis, liver and skeletal muscle [25]. It has also been
shown to be alternatively spliced, producing at least five
splice variants with the same open reading frame in
human cells [25,26]. Expression analysis ascertained so
far for variants I and II in normal tissues [25] shows
prevalent expression of splice variant I. The role of the
other variants in processes like apoptosis, cell signaling
and migration, remains unclear. Analysis of the potential
variations in HAX1 splicing patterns in tumors may
shed some light on the role of splice variants in cancer
pathology.
The involvement of HAX-1 in processes crucial to
carcinogenesis as well as demonstration of its over-
expression in several tumor cell lines provides strong
arguments for a detailed analysis of its role in neoplastic
transformation and metastasis. In this report, we present
for the first time a focused analysis of HAX1 expression
in several solid tumors, identifying three malignant neo-
plasms (breast cancer, lung cancer and melanoma) in
which HAX1 is significantly up-regulated. Detailed ana-
lysis of expression of five splice variants of HAX1 in
breast cancer revealed tumor-specific variations in the
pattern of splicing. HAX-1 elevated expression in breast
cancer was confirmed at the protein level, by immuno-
histochemistry, which also revealed its nuclear localiza-
tion in ER-positive tumors. Expression results were
validated against clinical data, including stage and grade
of tumor, receptor and nodal status. Additionally, the
influence of estrogen on HAX1 expression was esti-
mated in a breast cancer estrogen-responsive cell line
(MCF-7) and found not significant.
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Breast cancer samples
Breast cancer samples were obtained from 15 breast
cancer patients (median age 64 years, range 32-81 years)
undergoing surgery at the Cancer Center - Institute of
Oncology in Warsaw. Samples were diagnosed according
to histopathological reports as primary invasive carcino-
mas (ductal, lobular, papillary and mixed). Paired sam-
ples of breast carcinoma and normal tissue adjacent to
the carcinoma were collected from each patient. These
tissues are referred to as ‘normal’ breast tissues,
although they cannot be regarded as completely ‘healthy
normal’ specimens. A detailed description of the breast
carcinomas of the 15 patients is shown in Table 1. This
study was approved by the local ethics committee and
the patients gave an informed consent about the usage
of tissues for research purposes.
Oncology qPCR arrays
The following oncology qPCR arrays were purchased
from OriGene Technologies (Rockville, MD, USA) and
used to asses human HAX-1 mRNA expression levels:
TissueScan Oncology Survey Tissue qPCR Array I, Tis-
sueScan Breast Cancer Tissue qPCR Array II, TissueS-
can Lung Cancer Tissue qPCR Array III, TissueScan
Melanoma Tissue qPCR Array. All the clinical and
pathological information associated with samples in
each of the panels can be found on the OriGene website
http://www.origene.com/geneexpression.
Tissue sampling
Breast cancer and adjacent normal tissue samples were
selected by a pathologist from surgically removed tissues
of breast cancer patients immediately after surgery.
Samples were flash-frozen, pulverized in liquid nitrogen
using Microdismembrator II (Braun Biotech, Aylesbury,
UK) and stored at -80°C prior to RNA isolation.
RNA isolation and cDNA synthesis
RNA from 30 - 90 mg of pulverized breast cancer tissue
and normal controls from the same patient was isolated
using NucleoSpin RNA II kit (Macherey - Nagel, Düren,
Germany). RNA from 5×10
5 MCF-7 or Hela cells was
isolated using PureLink Micro-to-Midi Total RNA Puri-
fication Kit (Invitrogen, Carlsbad, CA, USA). The
amount and purity of RNA were measured spectro-
photometrically on NanoDrop ND-1000 (NanoDrop
Technologies, Wilmington, DE, USA). Overall RNA
integrity and quality was assessed on a denaturing agar-
ose gel. Genomic DNA was removed from RNA samples
by digestion with recombinant DNase I, RNase-free
(Roche, Mannheim, Germany) according to the manu-
facturer’s instructions. First strand cDNA was synthe-
sized from 50 ng (for semi-quantitative PCR on patient
samples), 200 ng (for quantitative PCR on patient sam-
ples) or 1 μg (MCF-7 and Hela cells) of total RNA using
25 ng oligo(dT)18 primers (Fermentas, Burlington,
Canada) and SuperScript II, RNase H - Reverse Tran-
scriptase (Invitrogen) according to the manufacturer’s
instructions. Reverse transcription was repeated at least
twice to minimize the effects of possible differences in
reverse transcription efficiency amongst samples.
Reverse transcription semi-quantitative PCR
Expression of HAX-1 splicing variants in breast cancer
versus normal tissue was analyzed using reverse tran-
scription semi-quantitative PCR. Splice variant nomen-
clature is presented as in Carlsson et al. [25]. Primers
for PCR were designed to amplify HAX1 variant I, II
and III specifically, primers for variants IV and V have
been described previously [26]. Primers for GAPDH
were described elsewhere [27]. Primer sequences are
Table 1 Tumor characteristics of the 15 patients’ primary
carcinomas
Characteristic n %
Size (cm)
< 2 5 33.3
> 2 10 66.7
Nodal status
Positive 9 60
Negative 6 40
Histology
Ductal 7 46.7
Lobular 3 20
Papillary 4 26.7
Mixed 1 6.6
Stage
I 1 6.7
IIA 8 53.3
IIB 4 26.7
IIIA 2 13.3
Grade
13 2 0
29 6 0
3 2 13.3
ER status
Positive 9 60
Negative 6 40
PR status
Positive 8 53.3
Negative 7 46.7
HER2 status
Positive 7 46.7
Negative 8 53.3
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corresponding to 2.5 ng (for HAX1 variant I and
GAPDH), 5 ng (for HAX1 variant II) or 10 ng (for
HAX1 variant III, IV and V) of total RNA was amplified
using Taq DNA Polymerase (Invitrogen), 200 nM dNTP
(Fermentas) and 100 nM of the appropriate primers.
PCR conditions were: 95°C (5 minutes) followed by
cycles of 95°C (30 seconds), 57°C (30 seconds), and 72°C
(30 seconds). Cycle numbers for linear amplification of
HAX1 were as follows: variant I - 35, HAX1 variant II -
35, HAX1 variant III - 40, HAX1 variant IV and V - 40,
GAPDH - 30 cycles. The experiment was independently
repeated thrice.
Reverse transcription quantitative PCR
Expression levels of HAX1 splicing variants in oncology
qPCR arrays and breast cancer samples versus normal
tissues as well as transcripts levels in cells treated with
beta-estradiol were assessed using quantitative PCR on
an ABI Prism 7000 Sequence Detection System (Applied
Biosystems, Foster City, CA, USA) with human ACTB
as a reference gene. Amplification mixtures (25 μl) con-
tained 10 ng (samples obtained from patients) or 20 ng
(MCF-7 and Hela cells) of cDNA template, 1×SYBR
Green I Master Mix Buffer (Applied Biosystems) and
100 nM of the appropriate forward and reverse primer.
Primers used for amplification of HAX1 variant I were
the same as in semi-quantitative PCR. Primer sequences
for HAX1 variant II and cathepsin D (CTSD) are shown
in Table 2. Primers for the reference gene ACTB were
described previously [28]. The cycling conditions for
HAX1 splicing variants were as follows - precycling hold
at 95°C for 10 minutes, 40 cycles: 95°C for 30 seconds
and 60°C for 60 seconds; for CTSD - precycling hold at
95°C for 10 minutes, 40 cycles: 95°C for 30 seconds,
57°C for 30 seconds, 72°C for 30 seconds; for ACTB -
precycling hold at 95°C for 10 minutes, 40 cycles: 95°C
for 30 seconds, 55°C for 30 seconds, 72°C for 30 sec-
onds. To assess specificity, amplification products were
subjected to melting curve analysis. Raw data were ana-
lyzed using ABI Prism 7000 SDS Software Version 1.1
(Applied Biosystems). Relative expression levels were
calculated using efficiency-corrected Ct model which
takes into account amplification efficiencies of each pri-
mer pair [29].
Estrogen activation
MCF-7 estrogen-dependent breast cancer cells and
HeLa (human cervical carcinoma) cells were precondi-
tioned for a week in D-MEM (Invitrogen) with char-
coal-stripped FBS (Sigma-Aldrich, MO, USA) and
subjected to the treatment with the indicated concentra-
tions of beta-estradiol (Sigma-Aldrich) for 48 h [30].
cDNA obtained from the treated cells was analyzed by
qPCR with primers specific for HAX1,v a r i a n t sIa n dI I
(as above), CTSD and ACTB.
Immunohistochemical analysis
Immunohistochemical stainings were performed on par-
affin-embedded material after heat-induced epitope
retrieval (HIER). A mouse monoclonal anti-HAX-1 anti-
body was used at a concentration of 1:75 (BD Transduc-
tion Laboratories, USA). Antigens were retrieved by
heating the sections in 0.01 M citrate buffer (pH 6.0)
6 × 5 min. in a microwave oven at 700 W. Non-specific
tissue and endogenous peroxidase reactivity were
Table 2 Primers’ sequences
mRNA forward primer reverse primer
HAX1 variant I 5’-GACCTCGGAGCCACAGAGAT-3’ 5’-GGTGCTGAGGACTATGGAAC-3’
GenBank: NM_006118
HAX1 variant II 5’-GGACCTCGGAGCTTCAG-3’ 5’-TGACTCAGGACCTGGAAGTT-3’ (semi-qPCR)
GenBank: NM_001018837 5’-CCATATCGCTGAAGATGCTA-3’ (qPCR)
HAX1 variant III 5’-GACCTCGGAGGTGAGA-3’ 5’-CCATATCGCTGAAGATGCTA-3’
GenBank: EU190983
HAX1 variant IV 5’-AGGAATTTGGCTTCGGCTTC-3’ [26] 5’-TGCAGAAAGGTGGCAGGTGTT-3’ [26]
GenBank: EU190982 and HAX1 variant V
VEGA:OTTHUMT00000087654
CTSD 5’-GCTGTGAGGCCATTGTGGAC-3’ 5’-GCGACACCTTGAGCGTGTAG-3’
GenBank: NM_001909
GAPDH 5’-GGTCGGAGTCAACGGATTTG-3’ [27] 5’-ATGAGCCCCAGCCTTCTCCAT-3’ [27]
GenBank: NM_002046
ACTB 5’-AGCCTCGCCTTTGCCGA-3’ [28] 5’-GCGCGGCGATATCATCATC-3’ [28]
GenBank: NM_001101
Sequences of the primers used in reverse transcription semi-quantitative and quantitative PCR. GeneBank accession numbers are indicated for each transcript
except for variant V where transcript ID from Vertebrate Genome Annotation (VEGA) database is shown.
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sections were incubated with primary antibodies over-
night at 4°C. The binding of the primary antibody was
detected by a Vectastain Elite ABC kit (Vector Labora-
tories, Burlingame, CA, USA) and DAB was used as a
chromogen. Slides were counterstained with Mayer’s
hematoxylin. Normal mouse IgG of the same subclasses
and concentrations as the primary antibody served as
negative controls.
Statistical analysis
Statistical analysis was performed using Statistica 6.0
(StatSoft, Inc., OK, USA). Nonparametric Mann-Whit-
ney test and Wilcoxon test for matched pairs’ analysis
were used to analyze mRNA expression data. Fisher’s
exact test was used to determine statistical significance
of the IHC data. A P-value of < 0.05 was regarded as
statistically significant.
Results
HAX1 expression level is elevated in breast and lung
cancers and in melanoma
In a preliminary screen, performed in order to asses
HAX1 expression levels in different solid tumors, a survey
panel containing cDNA from 96 tissue samples, covering
8 different cancers (breast, colon, kidney, liver, lung, ovar-
ian, prostate, thyroid) was used (TissueScan Oncology
Survey Tissue qPCR Array I). The samples represented
disease stages from 0 to III or IV. Expression levels of all
panel data were ascertained by quantitative PCR. Expres-
sion of splice variant I was assessed and considered as
representative for overall HAX1 expression, on the basis
of its prevalence in respect to other variants (as shown in
this study in section “HAX1 splice variants expression in
normal vs. tumor samples of breast cancer” and in Carls-
son et al., 2008 [25]). Statistical significance for panel
data was assessed using the nonparametric Mann-Whit-
ney test. The highest levels of expression, significantly
exceeding the level of normal control, were observed in
breast and lung cancers (Fig 1A and 1B). In these two
panels, up-regulation is significant in the most advanced
stages of the disease (stages III-IV, P = 0.025 and 0.049
for breast and lung cancer, respectively). For the rest of
the analyzed tumors, no significant overexpression or
relation was observed, except for colon cancer, where sig-
nificant up-regulation was detected for stages I-II (Fig
1C, D, E, F, G and 1H). Since our study was focused on
finding a relationship between HAX1 expression levels
and factors related to metastasis, such as stage, nodal sta-
tus and grade of the disease, colon cancer was excluded
from further analysis because of a non-significant p-level
value for stages III-IV.
To further verify the results obtained from the survey
panel, and to narrow the analysis, three other panels -
breast cancer, lung cancer and melanoma - were ana-
lyzed, each containing cDNA from 48 tissue samples for
each cancer type. Melanoma was included because of
the potential role of HAX-1 in skin diseases and its
reported overexpression in melanoma cell lines [22].
Panels contained samples from different stages of dis-
ease, including metastatic carcinomas (2, 7 and 40 cases
for breast cancer, lung cancer and melanoma,
respectively).
Detailed analysis of the expression data obtained from
these specific panels was performed using non-para-
metric Mann-Whitney test and confirmed HAX1 signifi-
cant up-regulation in tumors, though not as high as
previously detected in the survey panel (Fig 2). The
most marked results were obtained for breast cancer
samples, with significant overexpression (in regards to
stage 0) for all subsequent stages of the disease (Fig 2A).
In lung cancer samples, significant overexpression was
obtained for stages I and IV, with higher expression
levels and higher significance for stage IV (Fig 2B). The
melanoma tissue panel was composed of normal and
exclusively metastatic carcinoma samples from stages III
and IV. Significant overexpression was obtained for both
groups, with higher significance for stage IV (Fig 2C).
HAX1 splice variants expression in normal vs. tumor
samples of breast cancer
Human HAX1 pre-mRNA is alternatively spliced to gen-
erate at least 8 splice variants [25,26]. Five of these var-
iants remain in the same reading frame, while the rest
contains a frameshift, generating a different protein pro-
d u c t .I nt h i sa n a l y s i sw ea s c e r t a i n e dt h ee x p r e s s i o n
levels for the first five splice variants in the same read-
ing frame (Fig 3).
Since the previous study in which the expression of
splice variants I and II was compared [25] revealed that
variants’ expression levels vary considerably (with the
prevalence of splice variant I), to further demonstrate
possible differences in expression the relative mRNA
levels of the all five variants were assessed by standard
RT-PCR. The results show that while variant I is quite
abundant and easily detectable by 30 PCR cycles (Fig
4A), the expression of the other variants is quite weak
(visible bands at 40 cycles, Fig 4A).
Samples of normal (adjacent to tumor) and tumor tis-
sues from the same patient were analyzed for 15 breast
cancer cases (Table 1). This type of material enables
matched pair analysis, which eliminates differences in
expression arising from the variability of genomic back-
ground. Expression of splice variants I, II, III, IV and V
were analyzed by standard RT-PCR, with GAPDH as a
reference (Fig 4B). The most marked difference in
expression was detected in case of variant III. In 8
paired samples the expression of the splice variant III
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Page 5 of 16Figure 1 HAX1 (splice variant I) expression levels in eight different solid tumors. HAX1 expression is significantly elevated in breast (A),
lung (B) and colon (C) cancers, while in kidney (D), liver (E), ovary (F), prostate (G) and thyroid (H) cancers up-regulation was not detected.
Quantitative data from cDNA panels were analyzed using the nonparametric Mann-Whitney test. Statistical significance was denoted under the
box-whiskers plots for values of P < 0.05. In breast and lung cancers significant overexpression was observed for the advanced stages (III-IV),
while in colon cancer for early stages (I-II).
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Page 6 of 16Figure 2 HAX1 (splice variant I) expression analysis in disease-focused panels representing breast cancer (A), lung cancer (B) and
melanoma (C). Data were analyzed using non-parametric Mann-Whitney test and statistical significance for values of P < 0.05 was denoted
under the plots. For breast cancer samples significant overexpression level was detected in all stages (I, II, III and IV). Analysis of the lung cancer
samples show significant overexpression for stages I and IV. For melanoma, HAX1 expression in all analyzed stages was significantly up-regulated
(only stages III and IV were analyzed).
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Page 7 of 16was detected only in tumors, while in the remaining 7
samples expression of variant III was detected neither in
tumors nor in normal tissues, except for one case, in
which the expression was detected in normal tissue and
not in tumor. For the other variants the differences in
expression were not detectable in the standard PCR
experiment, apart from slight overexpression of variant
V in six cases out of fifteen (Fig 4B).
Expression of variants I and II was relatively high
(although much higher for variant I), which made it
possible to reliably and precisely assess its levels by
quantitative PCR. For both variants up-regulation in
tumors was statistically significant (P = 0.047 and P =
0.02 for variants I and II, respectively, nonparametric
Wilcoxon test for matched pairs). The results also
demonstrated, that although the high expression of
the splice variant I in respect to the other variants
(observed previously for the normal tissues, [25])
remains very high in tumors, the median value of the
variant I/variant II expression ratio is considerably
lower in tumor than in the matching normal tissues: 9
(6.63-11.23) and 15 (10.97-17.01), for tumor and nor-
mal tissues, respectively (Fig 5A). Accordingly, the rela-
tive tumor overexpression level in most cases (13
patients, 87%) is higher for variant II than for variant I
(Fig 5B).
Figure 3 Alternative splicing of the human HAX1. Only five splice variants, generating putative protein product maintained in the same
reading frame are depicted. Variants are named as in Carlsson et al., 2008 [25], nomenclature from Lees et al., 2008 [26] in brackets. The location
of the variant-specific primers is depicted by arrows.
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Page 8 of 16Figure 4 Expression of the five HAX1 splice variants detected by semi-quantitative PCR.A .E x p r e s s i o no ft h ef i v eHAX1 splice variants
detected in the normal breast tissue reveals significant differences in expression levels, showing the prevalence of splice variant I. Normal breast
tissue cDNA, splice variants I-V, 30 and 40 cycles. B. HAX1 splice variants expression in all 15 patients. The most marked difference was detected
for variant III, the amplification of which was observed only in tumors in eight cases. In the remaining 7 cases no amplification was detected,
except for patient 13, where a weak band was detected in the normal tissue sample, but not in the tumor sample. Higher amplification in
tumors can be also observed in some patients for variant V (patients 1, 5, 7, 8, 11,13).
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Page 9 of 16Figure 5 Quantitative analysis of the expression of HAX1 variants I and II. A. Expression of variant I is significantly higher than variant II, in
both, normal and tumor tissues, but variant I/variant II expression ratio is higher in normal tissues (median 15) than in tumors (median 9), due
to a relatively higher overexpression of variant II in tumors. B. Relative overexpression measured for variant I and variant II, calculated as a tumor/
normal ratio. Overexpression, (expression higher than 1.5 fold) was found in 47% and 73% of cases for variants I and II, respectively. Dashed line
indicates the level of expression in normal tissues. Order of patients according to the stage of the disease.
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characteristics
HAX1 expression levels were analyzed in respect to prog-
nostic markers other than stage of the disease, in order
to establish possible relationships. Factors like tumor size,
grade of the disease, nodal status and histology were used
to categorize data, followed by statistical analysis of the
groups. For breast cancer, receptor status (ER, PR and
HER2) was additionally included in the analysis. Data
from the cDNA panel of breast cancer samples showed a
significant relationship between HAX1 expression levels
and tumor size (P = 0.004 and P = 0.0015 for T0 vs. T1
and T0 vs. T2-4, respectively) and grade (P = 0.003 and
P = 0.0015 for G0 vs. G1-2 and G0 vs. G3, respectively),
but for the other prognostic markers no significant rela-
tion was detected. For the other two panels, pathology
reports concerning tumor size and grade were not suffi-
cient to perform the analysis in the case of melanoma,
and showed no relationship in the case of lung cancer.
Data from the matched pairs of normal and tumor tis-
sue samples from the 15 patients were analyzed sepa-
rately. The relationships between variants I and II
expression levels and the established breast cancer prog-
nostic factors were calculated and are summarized in
Table 3. The most significant relationship was found,
again, for tumor size (P = 0.005, same value for variants
I and II). Relationships of weak significance (borderline)
were found for nodal status (inverse relationship, var-
iants I and II), progesterone-negative cancers (variants I
and II) and HER2-negative cancers (variant II). Estrogen
receptor status had no relation to HAX1 expression
level, which confirms the results obtained from the
panel data analysis.
Estrogen does not regulate HAX1 mRNA levels
The MCF-7 estrogen-dependent breast cancer cell line
was subjected to treatment with the indicated concentra-
tions of beta-estradiol (Fig 6A). Concurrently, the same
experiment was performed in HeLa cells as an estrogen-
independent reference (Fig 6B). The levels of HAX1
expression for the two splice variants (I, II) in estradiol-
treated cells were established by quantitative PCR. The
effect of estrogen was assessed in comparison to the
known up-regulation of expression observed for cathepsin
D mRNA [30]. No significant HAX1 up- or down-regula-
tion was observed for any of the splice variants. This
result is consistent with the lack of relation between
HAX1 expression levels and the ER status, in the samples
from cDNA panels and from patients (Table 2).
HAX-1 overexpression in tumors and partial localization
in cell nuclei was detected at the protein level
HAX1 up-regulation detected at the mRNA level was
confirmed at the protein level by immunohistochemical
analysis. Paraffin sections of the paired normal and
tumor tissues from all fifteen patients were analyzed.
HAX-1 up-regulation was detected in most of the
tumor samples (Table 4, Fig 7A and 7B). Intensive
HAX-1 staining was observed not only in the cytoplasm
(Table 4, Fig 7B), but also in the nuclei of the tumor
cells (Table 4, Fig 7A). In the matching normal cells
cytoplasmic staining was minimal (Table 4, Fig 7G and
7H) and nuclear staining was not detected (Table 4, Fig
7G). IgG controls of the analyzed tissue sections were
negative (Fig 7E and 7F). It was observed, that strong
nuclear HAX-1 staining was associated with strong ER
staining (Table 4, Fig 7A and 7C), while cytoplasmic
HAX-1 staining coincided with weak ER staining (Table
4, Fig 7B and 7D); this relation was calculated by the
Fisher’s exact test and found significant (P = 0.026).
Table 3 Relation of HAX1 expression to breast cancer
prognostic factors
Characteristic n HAX1 (I) expression: HAX1 (II) expression:
median of relative over-
expression (lower and
upper quartile values)
median of relative over-
expression (lower and
upper quartile values)
Size (cm)
< 2 5 0.82 (0.35-1.30) 0.82 (0.41-2.04)
> 2 10 2.2 (1.38-4.15)* 2.99 (1.70-7.5)*
Nodal status
Positive 9 1.3 (1.54-4.15) 1.7 (0.82-2.90)
Negative 6 2.35 (0.82-2.18) 4.05 (2.04-7.75)*
Histology
Ductal 7 1.3 (0.36-2.23) 2.04 (0.41-3.34)
Lobular 3 1.38 (1.33-2.83) 2.62 (1.54-5.50)
Papillary 4 3.77 (2.03-7.10) 6.81 (1.87-14.46)
Mixed 1 1.08 1.7
Grade
1 3 1.3 (0.36-1.54) 2.04 (0.41-2.89)
2 9 1.88 (1.08-2.83) 2.62 (1.09-5.48)
3 2 3.17 (2.18-4.15) 5.2 (2.65-7.75)
ER status
Positive 9 1.33 (1.08-1.54) 2.04 (1.55-2.89)
Negative 6 2.51 (1.88-4.15) 4.06 (1.09-7.75)
PR status
Positive 8 1.32 (0.95-1.46) 1.9 (1.18-2.76)
Negative 7 2.23 (1.88-4.15) 3.34 (1.09-7.75)*
HER2 status
Positive 7 1.30 (0.82-1.54) 1.7 (0.82-2.89)
Negative 8 2.51 (1.63-4.75) 4.06 (1.86-9.36)*
* denotes a P-value of < 0.005
Relationship between the expression of the HAX1 splice variants I and II and
established prognostic factors in breast cancer. Median of relative
overexpression was calculated for each group (lower and upper quartile
values in parenthesis). Statistical significance was denoted in the groups were
the number of cases was sufficient to perform the Wilcoxon matched-pairs
test (size, nodal status, ER, PR, HER2 status) and a P-value of < 0.05 was
observed.
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Page 11 of 16HAX-1 nuclear localization was also observed by
immunofluorescence in about 21% of cells in HAX-1-
GFP-transfected MCF-7 breast cancer cell line, thus
confirming IHC data, indicating that HAX-1 is present,
at least to some extent, in the nuclei of breast cancer
cells (Additional files 1 and 2).
Discussion
HAX-1 protein has been reported to play a role in
apoptosis and cell migration, its overexpression has
been detected in cancer cell lines and - mostly by
microarray analysis - in tumors, but hitherto, no sys-
tematic screen of its expression in cancer has been per-
formed. This report represents the first preliminary
analysis of HAX1 expression levels in solid tumors.
The initial survey, performed for a cDNA panel con-
taining samples from eight different solid tumors
revealed significant HAX1 overexpression for stages III-
IV of breast and lung cancer. The samples derived from
the other six cancers (colon, kidney, ovary, liver, pros-
tate, thyroid) did not show significant changes in HAX1
expression, except for stages I-II of colon cancer.
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Figure 6 Estrogen has no effect on HAX1 expression. Preconditioned cells were treated with the increasing concentrations of beta-estradiol
for 48 h. mRNA levels of HAX1 and estrogen-dependent cathepsin D mRNA were measured by quantitative PCR. A. Estrogen-dependent breast
cancer cell line MCF-7. B. HeLa cell line.
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Page 12 of 16An extended analysis of specific cDNA panels, con-
taining a larger number of samples from different dis-
ease stages, confirmed the presence of statistically
significant overexpression in breast and lung cancer and
additionally, in melanoma. Detailed statistical analysis of
these data has shown that for breast cancer and mela-
noma HAX1 is significantly overexpressed in subsequent
stages, with higher significance for later stages. For
breast cancer, a similar relation was observed for tumor
size and histological grade, but no relation was detected
for other prognostic markers such as nodal status and
receptor status (ER, PR and HER2). The number of
cases with metastatic disease for breast and lung cancer
was not sufficient to calculate a relation between HAX1
overexpression and the presence of distant metastases.
In the case of melanoma all tumor samples were derived
from cancers with distant metastases, which also
excluded the possibility of comparing the expression in
primary and metastatic tumors. Detailed examination of
the data from the lung cancer panel did not confirm
high overexpression status detected previously in the
survey panel, but nevertheless, a significant overexpres-
sion was observed for the samples from stages I and IV.
Therefore, panel analysis provided evidence for the
expected HAX1 overexpression in tumors and identified
specific tumors in which such overexpression takes
place. Our results indicate the relation of HAX1 expres-
sion to tumor size, stage and grade of the disease but
more detailed analysis is needed to confirm if the
observed relationships are in any way connected to a
potential role for HAX-1 in metastasis. The lack of rela-
tionship between HAX1 expression and nodal status
does not support such a hypothesis, but it still needs to
be verified on a larger scale.
cDNA panel analysis produced results which are par-
tially consistent with the microarray-generated data
deposited in Oncomine (overexpression in lung cancer
and melanoma, grade-specific overexpression in breast
cancer), but there are also substantial differences (lack
of significant overexpression in hepatoma).
To further analyze HAX1 up-regulation in breast can-
cer, matching pairs of tumor and normal adjacent tis-
sues from 15 breast cancer patients were examined,
confirming significant overex p r e s s i o ni nt u m o rt i s s u e .
The differential samples under analysis represented sev-
eral types of tumor (ductal, lobulary, papillary and
mixed carcinomas) with different tumor size, nodal and
receptor status. The group was too uniform in respect
o fg r a d ea n ds t a g eo ft h ed i s e a s et oc o n f i r mt h er e l a -
tionship of these factors to HAX1 expression level. The
analysis of other prognostic markers demonstrated a sig-
nificant relation between HAX1 expression level and
tumor size, which confirms the results obtained from
the cDNA panel. No relation was detected for receptor
status, again, confirming the results from the panel. The
relationships found for nodal status, progesterone and
HER2 status were of borderline significance and since
they were not confirmed by the panel data, their reliabil-
ity is doubtful. In general, data from matched-pair ana-
lysis are largely consistent with the data obtained from
the cDNA breast cancer panel. The discrepancies are
minor and can be explained by the small number of
cases in the matched-pairs analysis.
Matched pairs of tumor and normal tissues were also
used to determine the variations of HAX1 splicing pat-
tern in breast cancer samples. Detailed quantitative ana-
lysis was possible only for splice variants I and II,
because the expression of the other variants is barely
detectable, and is therefore likely to produce ambiguous
quantitative results. All five variants were however ana-
lyzed by standard RT-PCR. The results revealed that
HAX1 splicing pattern in breast cancer is indeed slightly,
but recurrently different than in normal tissues. Variant
I expression remains high in normal and tumor tissues,
compared to the expression of the other variants, but
variant II levels are reproducibly higher in tumors
(Fig 5), pointing to its specific up-regulation. The most
marked difference in the splicing pattern was detected
Table 4 IHC analysis confirms HAX-1 overexpression in
tumors
Patient HAX-1 ER
Normal Tumor Tumor
Cytoplasm Nucleus Cytoplasm Nucleus Nucleus
10 - 2 - +
2 0/1 - 1 - -
31 - 1 - -
40 - 0 - -
50 - 1 - -
60 - 1 - -
71 - 0+ +
80 - 2+ +
90 - 1 - -
10 2 - 2 - +
11 1 - 1/2 - +
12 0 - 2 + +
13 0 - 2 - -
14 0 - 2 + +
15 0 - 3 - -
Immunohistochemical analysis of the 15 matched pairs of normal/tumor
samples shows in most cases significant overexpression of HAX-1 in tumors.
Up-regulation was observed in cytoplasm as well as nuclei of the tumor cells.
Staining intensity was estimated as follows: negative = 0; weak = 1;
intermediate = 2; and strong = 3. Nuclear staining was categorized as
negative or weak (0-1:"-”) and intermediate-strong (2-3: “+”). Strong nuclear
HAX-1 staining was associated with strong ER immunopositivity. Fisher’s exact
test indicates that nuclear staining of HAX-1 and ER is significantly related
(P = 0.01).
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Page 13 of 16Figure 7 Representative immunohistochemical staining of the analyzed breast cancer samples shows elevated levels of HAX-1 in
tumor tissues. Each column represents samples from one patient. HAX-1 staining was detected in the nuclei (A) and the cytoplasm (B) of
tumor cells (magnification × 400). Nuclear HAX-1 localization was observed only in the strongly ER-positive samples (C), while in the samples
with cytoplasmic HAX-1 staining ER expression was weak (D). Control samples incubated with mouse IgG of the same subclasses and
concentrations as the primary antibody (E and F) were negative. Normal samples from the analyzed two patients (G and H) do not show visible
HAX-1 staining.
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Page 14 of 16for splice variant III; its expression in normal samples
could not be detected by standard RT-PCR, probably
due to combined effects of its very low expression level
and a relatively small amount of the obtained cDNA,
but in more than a half of the samples a clear PCR pro-
duct was detected in tumor samples (Fig 4). These
results suggest that variant III expression could be
tumor-specific. Up-regulation of the HAX1 alternative
splice variants in cancer indicates their specific role, but
cannot be explained until specific functions would be
attributed to the different splice variants and their corre-
sponding putative protein products.
HAX-1 overexpression in breast cancer samples was
confirmed at the protein level by immunohistochemis-
try. Although the reaction is not standardized (as in the
case of known markers), the expression was clearly up-
regulated in almost all tumor tissue sections analyzed
(Table 4). Overexpression was detected, as expected, in
the cytoplasm, but also in the nuclei of tumor cells,
which is inconsistent with previous findings, associating
HAX-1 with cytoplasmic structures (ER and lammelipo-
dia, [31]; ER and mitochondria, [1,15]; mitochondria,
[7,9]. Suzuki et al., [15] observed HAX-1 at the nuclear
envelope, but this location was never confirmed in sub-
sequent reports. Location of Hax-1 in the nuclear matrix
was previously detected in normal rat testis [32].
Nuclear localization of HAX-1 has also been observed
in systemic sclerosis fibroblasts [33]. The latter repre-
sents so far the only report suggesting that this localiza-
tion might be disease-dependent. Results presented here
implicate, that the nuclear localization of HAX-1 might
be also associated with some types of cancer.
HAX-1 overexpression detected in breast cancer,
where estrogen receptor status is an obvious prognostic
factor, combined with some literature data indicating
possible induction of HAX1 by estrogen [11,12] provided
reasons to ascertain the influence of the estrogen treat-
ment on HAX1 expression. The results show clearly
that, in spite of previous predictions, HAX1 mRNA
expression level is estrogen-independent. This finding is
in agreement with the lack of a relation between HAX1
expression levels and ER status in breast cancer samples.
However, estrogen may regulate HAX-1 activity in some
other, non-genomic way. The observed relation between
nuclear localization of HAX-1 and estrogen receptor
up-regulation suggests thate s t r o g e nm a yi n f l u e n c e
HAX-1 cellular localization. It has been observed [5]
that HAX-1-interacting protein, prohibitin, is translo-
cated to the nucleus upon estrogen treatment, and acts
as a repressor of ER activity. It remains to be established
if nuclear translocation of HAX-1 is also directly asso-
ciated with estrogen activity, but the observed correla-
tion points to this conclusion. There must be, however,
some other factors affecting HAX-1 localization, since
HAX-1-GFP-transfected MCF-7 breast cancer cells
show nuclear localization of this fusion in about 21% of
the analyzed cells (Additional Files 1 and 2), while estro-
gen treatment enhances nuclear localization only
slightly, to about 26% (data not shown).
Conclusions
This report provides evidence for HAX-1 up-regulation
in several types of solid tumors, confirming previous
estimations based on its anti-apoptotic activity, overex-
pression in cancer cell lines and scattered high-through-
put data. These preliminary results call for a more
detailed analysis to establish HAX-1 relation with
t u m o r i g e n e s i sa n dah i g h l yp r o b a b l ea s s o c i a t i o nw i t h
metastasis, along with clarification of the molecular
mechanisms behind HAX-1 cellular functions.
Additional file 1: HAX1 nuclear localization detected by
immunofluorescence. Methods and Results sections for detecting HAX-
1-GFP fusion protein in transfected MCF-7 breast cancer cell line. Nuclear
localization of the fusion protein was detected in about 21% of the cells.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-2407-10-
76-S1.PDF]
Additional file 2: HAX1 nuclear localization detected by
immunofluorescence (Figure 1). Figure showing nuclear presence of
the HAX-1-GFP fusion in MCF-7 breast cancer cell line.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-2407-10-
76-S2.PDF]
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